Cytokine and endocrine parameters in mouse chronic social defeat: Implications for translational 'cross-domain' modeling of stress-related brain disorders

Behavioural Brain Research

Volumn 276, Issue , 2015, Pages 84-91

  Stewart, Adam Michael ^a,b   Roy, Sudipta ^b   Wong, Keith ^b   Gaikwad, Siddharth ^b   Chung, Kyung Min ^b   Kalueff, Allan V ^a,b  

^a ZENEREI Institute   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Corticosterone; Cytokine; Mice; Social defeat; Stress

Indexed keywords

CORTICOSTERONE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AFFECT; ANIMAL EXPERIMENT; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; IMMUNOPHENOTYPING; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SOCIAL BEHAVIOR; SOCIAL DEFEAT; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; DISEASE MODEL; MENTAL STRESS; PSYCHOLOGICAL MODEL;

ANIMALS; CORTICOSTERONE; CYTOKINES; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908563239     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.08.037     Document Type: Article

References (119)

1. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007, 41:189-206.
2. Nutt D. Treatment of depression and concomitant anxiety. Eur Neuropsychopharmacol 2000, 10(Suppl. 4):S433-S437.
3. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
4. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58:445-452.
5. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008, 18:230-233.
6. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157:683-694.
7. Anisman H., Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003, 35:2-11.
8. Anisman H., Merali Z., Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008, 85:1-74.
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
10. Leonard B.E., Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009, 24:165-175.
11. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
12. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002, 50:2041-2056.
13. Jonsdottir I.H., Hagg D.A., Glise K., Ekman R. Monocyte chemotactic protein-1 (MCP-1) and growth factors called into question as markers of prolonged psychosocial stress. PLoS ONE 2009, 4:e7659.
14. Hoge E.A., Brandstetter K., Moshier S., Pollack M.H., Wong K.K., Simon N.M. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety 2009, 26:447-455.
15. Lu Z.Y., Jensen L.E., Huang Y., Kealey C., Blair I.A., Whitehead A.S. The up-regulation of monocyte chemoattractant protein-1 (MCP-1) in Ea.hy 926 endothelial cells under long-term low folate stress is mediated by the p38 MAPK pathway. Atherosclerosis 2009, 205:48-54.
16. Asberg M., Nygren A., Leopardi R., Rylander G., Peterson U., Wilczek L., et al. Novel biochemical markers of psychosocial stress in women. PLoS ONE 2009, 4:e3590.
17. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009, 12:561-578.
18. Song C., Halbreich U., Han C., Leonard B.E., Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009, 42:182-188.
19. Koo J.W., Duman R.S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs 2009, 10:664-671.
20. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009, 23:1109-1116.
21. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34:2459-2468.
22. Ventriglia M., Zanardini R., Pedrini L., Placentino A., Nielsen M.G., Gennarelli M., et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:146-149.
23. Gillespie C.F., Bradley B., Mercer K., Smith A.K., Conneely K., Gapen M., et al. Trauma exposure and stress-related disorders in inner city primary care patients. Gen Hosp Psychiatry 2009, 31:505-514.
24. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006, 163:1630-1633.
25. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001, 933:222-234.
26. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008, 13:501-510.
27. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38:377-385.
28. Wrona D., Listowska M., Kubera M., Glac W., Grembecka B., Plucinska K., et al. Effects of chronic desipramine pretreatment on open field-induced suppression of blood natural killer cell activity and cytokine response depend on the rat's behavioral characteristics. J Neuroimmunol 2014, 268:13-24.
29. Wrona D., Listowska M., Kubera M., Majkutewicz I., Glac W., Wojtyla-Kuchta B., et al. Chronic antidepressant desipramine treatment increases open field-induced brain expression and spleen production of interleukin 10 in rats. Brain Res Bull 2013, 99:117-131.
30. Ojo J.O., Greenberg M.B., Leary P., Mouzon B., Bachmeier C., Mullan M., et al. Neurobehavioral, neuropathological and biochemical profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild traumatic brain injury. Front Behav Neurosci 2014, 8:213.
31. Slavich G.M., Irwin M.R. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 2014, 140:774-815.
32. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009, 34:4-20.
33. Pyter L.M., Pineros V., Galang J.A., McClintock M.K., Prendergast B.J. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A 2009, 106:9069-9074.
34. Reber S.O., Obermeier F., Straub R.H., Falk W., Neumann I.D. Chronic intermittent psychosocial stress (social defeat/overcrowding) in mice increases the severity of an acute DSS-induced colitis and impairs regeneration. Endocrinology 2006, 147:4968-4976.
35. Olatunji B.O., Wolitzky-Taylor K.B. Anxiety sensitivity and the anxiety disorders: a meta-analytic review and synthesis. Psychol Bull 2009, 135:974-999.
36. Price J., Sloman L., Gardner R., Gilbert P., Rohde P. The social competition hypothesis of depression. Br J Psychiatry 1994, 164:309-315.
37. Bjorkqvist K. Social defeat as a stressor in humans. Physiol Behav 2001, 73:435-442.
38. Hennessy M.B., Deak T., Schiml P.A. Sociality and sickness: have cytokines evolved to serve social functions beyond times of pathogen exposure?. Brain Behav Immun 2014, 37:15-20.
39. Piato A.L., Detanico B.C., Jesus J.F., Lhullier F.L., Nunes D.S., Elisabetsky E. Effects of Marapuama in the chronic mild stress model: further indication of antidepressant properties. J Ethnopharmacol 2008, 118:300-304.
40. Adams N., Blizard D.A. Effects of social defeat on acute cardiovascular response in salt-sensitive and salt-resistant rats. Behav Neural Biol 1986, 46:325-336.
41. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., Benoliel J.J. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 2008, 13:1079-1092.
42. Gardner K.L., Thrivikraman K.V., Lightman S.L., Plotsky P.M., Lowry C.A. Early life experience alters behavior during social defeat: focus on serotonergic systems. Neuroscience 2005, 136:181-191.
43. Keeney A., Jessop D.S., Harbuz M.S., Marsden C.A., Hogg S., Blackburn-Munro R.E. Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol 2006, 18:330-338.
44. Razzoli M., Carboni L., Guidi A., Gerrard P., Arban R. Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: a time-course study in the rat. Physiol Behav 2007, 92:734-740.
45. Yap J.J., Miczek K.A. Social defeat stress, sensitization, and intravenous cocaine self-administration in mice. Psychopharmacology (Berl) 2007, 192:261-273.
46. Bartolomucci A., Fuchs E., Koolhaas J.M., Ohl F. Acute and chronic social defeat: stress protocols and behavioral testing. Mood and anxiety related phenotypes in mice 2009, 261-275. Humana Press. T.D. Gould (Ed.).
47. Koolhaas J.M., De Boer S.F., De Rutter A.J., Meerlo P., Sgoifo A. Social stress in rats and mice. Acta Physiol Scand Suppl 1997, 640:69-72.
48. Schmidt M.V., Czisch M., Sterlemann V., Reinel C., Samann P., Muller M.B. Chronic social stress during adolescence in mice alters fat distribution in late life: prevention by antidepressant treatment. Stress 2009, 12:89-94.
49. Kudryavtseva N.N. Agonistic behavior: a model, experimental studies, and perspectives. Neurosci Behav Physiol 2000, 30:293-305.
50. Golden S.A., Covington H.E., Berton O., Russo S.J. A standardized protocol for repeated social defeat stress in mice. Nat Protoc 2011, 6:1183-1191.
51. Berton O., Durand M., Aguerre S., Mormede P., Chaouloff F. Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 1999, 92:327-341.
52. Krugers H.J., Koolhaas J.M., Bohus B., Korf J. A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. Neurosci Lett 1993, 154:73-77.
53. Rodgers R.J., Cole J.C. Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol Behav 1993, 53:383-388.
54. Tornatzky W., Miczek K.A. Long-term impairment of autonomic circadian rhythms after brief intermittent social stress. Physiol Behav 1993, 53:983-993.
55. Natalia P., Bondar I.L.K., Avgustinovich D.F., Smagin D.A., Kudryavtseva N.N. Anhedonia in the shadow of chronic social defeat stress, or when the experimental context matters. Open Behav Sci J 2009, 3.
56. Potegal M., Huhman K., Moore T., Meyerhoff J. Conditioned defeat in the Syrian golden hamster (Mesocricetus auratus). Behav Neural Biol 1993, 60:93-102.
57. Kinsey S.G., Bailey M.T., Sheridan J.F., Padgett D.A., Avitsur R. Repeated social defeat causes increased anxiety-like behavior and alters splenocyte function in C57BL/6 and CD-1 mice. Brain Behav Immun 2007, 21:458-466.
58. Razzoli M., Roncari E., Guidi A., Carboni L., Arban R., Gerrard P., et al. Conditioning properties of social subordination in rats: behavioral and biochemical correlates of anxiety. Horm Behav 2006, 50:245-251.
59. Veenema A.H., Meijer O.C., de Kloet E.R., Koolhaas J.M., Bohus B.G. Differences in basal and stress-induced HPA regulation of wild house mice selected for high and low aggression. Horm Behav 2003, 43:197-204.
60. Stefanski V. Social stress in loser rats: opposite immunological effects in submissive and subdominant males. Physiol Behav 1998, 63:605-613.
61. Carboni L., Piubelli C., Pozzato C., Astner H., Arban R., Righetti P.G., et al. Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 2006, 137:1237-1246.
62. Nikulina E.M., Hammer R.P., Miczek K.A., Kream R.M. Social defeat stress increases expression of mu-opioid receptor mRNA in rat ventral tegmental area. Neuroreport 1999, 10:3015-3019.
63. Kudryavtseva N.N., Bondar N.P., Avgustinovich D.F. Association between experience of aggression and anxiety in male mice. Behav Brain Res 2002, 133:83-93.
64. Kudryavtseva N.N., Sitnikov A.P. Influence of the genotype on the formation of aggressive and submissive behavior in mice. Neurosci Behav Physiol 1988, 18:38-43.
65. Kalueff A.V., Ren-Patterson R.F., LaPorte J.L., Murphy D.L. Domain interplay concept in animal models of neuropsychiatric disorders: a new strategy for high-throughput neurophenotyping research. Behav Brain Res 2008, 188:243-249.
66. Stewart A.M., Kalueff A.V. Anxiolytic drug discovery: what are the novel approaches and how can we improve them. Expert Opin Drug discov 2014, 9:15-26.
67. Stewart A.M., Kalueff A.V. Developing better and more valid animal models of brain disorders. Behav Brain Res 2014, [in press].
68. Denmark A., Tien D., Wong K., Chung A., Cachat J., Goodspeed J., et al. The effects of chronic social defeat stress on mouse self-grooming behavior and its patterning. Behav Brain Res 2010, 208:553-559.
69. Cannon T.D., Keller M.C. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol 2006, 2:267-290.
70. Gottesman M.M. Endophenotype. Encyclopedia of clinical psychology 2015, 1-23. Wiley-Blackwell, Hoboken, NJ. R. Cautin, S. Lilienfeld (Eds.).
71. Glahn D.C., Knowles E.E., McKay D.R., Sprooten E., Raventos H., Blangero J., et al. Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am J Med Genet B 2014, 165B:122-130.
72. Lenzenweger M.F. Thinking clearly about the endophenotype-intermediate phenotype-biomarker distinctions in developmental psychopathology research. Dev Psychopathol 2013, 25:1347-1357.
73. Kalueff A.V., Stewart A.M. Modeling neuropsychiatric spectra to empower translational biological psychiatry. Behav Brain Res 2014, [in press].
74. Kalueff A.V., Minasyan A., Keisala T., Shah Z.H., Tuohimaa P. Hair barbering in mice: implications for neurobehavioural research. Behav Process 2006, 71:8-15.
75. Kalueff A.V., Tuohimaa P. Grooming analysis algorithm for neurobehavioural stress research. Brain Res Brain Res Protoc 2004, 13:151-158.
76. Kalueff A.V., Tuohimaa P. The grooming analysis algorithm discriminates between different levels of anxiety in rats: potential utility for neurobehavioural stress research. J Neurosci Methods 2005, 143:169-177.
77. Kudryavsteva N.N. A sensory contact model for the study of aggressive and submissive behaviors in male mice. Aggress Behav 1991, 17:285-291.
78. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010, 37:519-533.
79. Cunningham E.T., De Souza E.B. Interleukin 1 receptors in the brain and endocrine tissues. Immunol Today 1993, 14:171-176.
80. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988, 80:1039-1044.
81. Aghajani M., Vaez Mahdavi M.R., Khalili Najafabadi M., Ghazanfari T., Azimi A., Arbab Soleymani S., et al. Effects of dominant/subordinate social status on formalin-induced pain and changes in serum proinflammatory cytokine concentrations in mice. PLOS ONE 2013, 8:e80650.
82. Mesquita A.R., Correia-Neves M., Roque S., Castro A.G., Vieira P., Pedrosa J., et al. IL-10 modulates depressive-like behavior. J Psychiatr Res 2008, 43:89-97.
83. Bergstrom A., Jayatissa M.N., Mork A., Wiborg O. Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res 2008, 1196:41-52.
84. Dahl J., Ormstad H., Aass H.C., Malt U.F., Bendz L.T., Sandvik L., et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45:77-86.
85. Derry H.M., Fagundes C.P., Andridge R., Glaser R., Malarkey W.B., Kiecolt-Glaser J.K. Lower subjective social status exaggerates interleukin-6 responses to a laboratory stressor. Psychoneuroendocrinology 2013, 38:2676-2685.
86. -/- mice. Atherosclerosis 2012, 221:359-365.
87. Wu X., He Y., Hsuchou H., Kastin A.J., Rood J.C., Pan W. Essential role of interleukin-15 receptor in normal anxiety behavior. Brain Behav Immun 2010, 24:1340-1346.
88. Pan W., Wu X., He Y., Hsuchou H., Huang E.Y., Mishra P.K., et al. Brain interleukin-15 in neuroinflammation and behavior. Neurosci Biobehav Rev 2013, 37:184-192.
89. Wu X., Hsuchou H., Kastin A.J., He Y., Khan R.S., Stone K.P., et al. Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Ralpha receptor. Psychoneuroendocrinology 2011, 36:266-278.
90. Lehto S.M., Huotari A., Niskanen L., Herzig K.H., Tolmunen T., Viinamaki H., et al. Serum IL-7 and G-CSF in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:846-851.
91. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16:751-762.
92. Vieira M.M., Ferreira T.B., Pacheco P.A., Barros P.O., Almeida C.R., Araujo-Lima C.F., et al. Enhanced Th17 phenotype in individuals with generalized anxiety disorder. J Neuroimmunol 2010, 229:212-218.
93. Juengst S.B., Kumar R.G., Failla M.D., Goyal A., Wagner A.K. Acute inflammatory biomarker profiles predict depression risk following moderate to severe traumatic brain injury. J Head Trauma Rehabil 2014, [in press].
94. Starkweather A.R., Lyon D.E., Schubert C.M. Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs 2013, 15:234-241.
95. Eisener-Dorman A.F. Genetic exploration of novel behavioral phenotypes in interleukin-7 and interleukin-18 receptor knockout mice 2008, State University of New York at Albany, New York.
96. Clark-Raymond A., Halaris A. VEGF and depression: a comprehensive assessment of clinical data. J Psychiatr Res 2013, 47:1080-1087.
97. Powell N.D., Sloan E.K., Bailey M.T., Arevalo J.M., Miller G.E., Chen E., et al. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via beta-adrenergic induction of myelopoiesis. Proc Natl Acad Sci U S A 2013, 110:16574-16579.
98. Iga J., Ueno S., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:658-663.
99. Tsai S.J., Hong C.J., Liou Y.J., Chen T.J., Chen M.L., Hou S.J., et al. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 2009, 169:113-117.
100. Tomita T., Yasui-Furukori N., Tsuchimine S., Kaneda A., Kaneko S. Relationships between vascular endothelial growth factor levels and temperament and character inventory traits in healthy Japanese subjects. Neuropsychobiology 2013, 69:1-5.
101. Halmai Z., Dome P., Dobos J., Gonda X., Szekely A., Sasvari-Szekely M., et al. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study. J Affect Disord 2013, 144:269-273.
102. Galecki P., Galecka E., Maes M., Orzechowska A., Berent D., Talarowska M., et al. Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:117-124.
103. Galecki P., Orzechowska A., Berent D., Talarowska M., Bobinska K., Galecka E., et al. Vascular endothelial growth factor receptor 2 gene (KDR) polymorphisms and expression levels in depressive disorder. J Affect Disord 2013, 147:144-149.
104. Fornaro M., Rocchi G., Escelsior A., Contini P., Ghio M., Colicchio S., et al. VEGF plasma level variations in duloxetine-treated patients with major depression. J Affect Disord 2013, 151:590-595.
105. Kahl K.G., Bens S., Ziegler K., Rudolf S., Kordon A., Dibbelt L., et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34:353-357.
106. Sharma A., Greenman J., Sharp D.M., Walker L.G., Monson J.R. Vascular endothelial growth factor and psychosocial factors in colorectal cancer. Psychooncology 2008, 17:66-73.
107. Aubrecht T.G., Weil Z.M., Magalang U.J., Nelson R.J. Dim light at night interacts with intermittent hypoxia to alter cognitive and affective responses. Am J Physiol Regul Integr Comp Physiol 2013, 305:R78-R86.
108. Dhabhar F.S., Saul A.N., Holmes T.H., Daugherty C., Neri E., Tillie J.M., et al. High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma. PLOS ONE 2012, 7:e33069.
109. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
110. Bowers S.L., Bilbo S.D., Dhabhar F.S., Nelson R.J. Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immun 2008, 22:105-113.
111. Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., et al. Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 2007, 179:5864-5876.
112. Sa-Rocha V.M., Sa-Rocha L.C., Palermo-Neto J. Variations in behavior, innate immunity and host resistance to B16F10 melanoma growth in mice that present social stable hierarchical ranks. Physiol Behav 2006, 88:108-115.
113. Grippo A.J. The utility of animal models in understanding links between psychosocial processes and cardiovascular health. Soc Pers Psychol Compass 2011, 5:164-179.
114. Stamou M., Streifel K.M., Goines P.E., Lein P.J. Neuronal connectivity as a convergent target of gene-environment interactions that confer risk for Autism Spectrum Disorders. Neurotoxicol Teratol 2013, 36:3-16.
115. Stankovic M., Lakic A., Ilic N. Autism and autistic spectrum disorders in the context of new DSM-V classification, and clinical and epidemiological data. Srp Arh Celok Lek 2012, 140:236-243.
116. Myhr G. Autism and other pervasive developmental disorders: exploring the dimensional view. Can J Psychiatry 1998, 43:589-595.
117. LaPorte J.L., Egan R.J., Hart P.C., Bergner C.L., Cachat J.M., Canavello P.R., et al. Qui non proficit, deficit: experimental models for 'integrative' research of affective disorders. J Affect Disord 2010, 121:1-9.
118. Andrus B.M., Blizinsky K., Vedell P.T., Dennis K., Shukla P.K., Schaffer D.J., et al. Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Mol Psychiatry 2012, 17:49-61.
119. Kalueff A., Stewart A., Gottesman I.I. Rethinking CNS disorders: time for new drug targets?. Trends Pharmacol Sci 2014, 10. [in press].